![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 18, 2021 1:38:34 PM
Any doctor will want zyesami. It worked better than the standard of care. Plus decrease hospitalisation by 10 days!
It didn't decrease hospitalization by 10 days. You can't say that as a blanket statement. It decreased hospitalization by 10 days for one subgroup and we don't even know how big that group was. When you have a tiny study, 195 patients, and further divide it into subgroups, you'll have some random good effects for some of the groups at some points. That is the law of probabilities. Also, it didn't work better than the standard of care. The mortality rate was higher in the treatment arm. So the study failed its primary endpoint and the secondary endpoint of mortality. I'm sure that RLFTF is praying that the mortality rate evens out at 60 days. But it is solely a hope. If you rewatch Dr Javitt in the Dr Yo interview, he starts breathing really heavy and almost starts crying when he explains the mortality data. It is obvious that the trial was a complete disappointment to him as he is forced into the lie that the mortality data will be better at day 60. Here is the video, go to the 6:30 point to see when he gets super emotional:
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM